BRISBANE, Calif., July 24 /EMWNews/ -- InterMune, Inc.

(Nasdaq: ITMN) announced today that it will release second quarter 2008

financial results and provide a business update on Thursday, July 31, 2008

at 4:00 p.m. Eastern time. A live conference call and webcast will be

hosted by InterMune at 4:30 p.m. Eastern time that same day.



    To access the live teleconference, dial 888-799-0528 (U.S.) or

706-634-0154 (international), conference ID# 57393097. To access the

webcast, please log on to the company's website at http://www.intermune.com

at least 15 minutes prior to the start of the call to ensure adequate time

for any software downloads that may be required.



    A replay of the webcast and teleconference will be available

approximately three hours after the call. The teleconference replay will be

available for 10 business days following the call and can be accessed by

dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering

the conference ID# 57393097.

    About InterMune



    InterMune is a biotechnology company focused on the research,

development and commercialization of innovative therapies in pulmonology

and hepatology. InterMune has a research and development portfolio

addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV)

infections. The pulmonology portfolio includes the Phase 3 program,

CAPACITY, which is evaluating pirfenidone for the treatment of patients

with IPF and a research program focused on small molecules for pulmonary

disease. The hepatology portfolio includes the HCV protease inhibitor

compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a

second-generation HCV protease inhibitor research program, and a research

program evaluating a new target in hepatology. For additional information

about InterMune and its R&D pipeline, please visit

http://www.intermune.com.